

# Care CEUs

## HIV/AIDS

### 1. Which of the following statements regarding PEP is most accurate?

- A. PEP must be started within three days after potential HIV exposure.
  - B. PEP must be started within four days after potential HIV exposure.
  - C. PEP must be started within five days after potential HIV exposure.
  - D. PEP must be started within six days after potential HIV exposure.
- 

### 2. When can a NAT usually detect HIV?

- A. Within 24 hours of exposure
  - B. Within 48 hours of exposure
  - C. About 5 to 10 days after exposure
  - D. About 10 to 33 days after exposure
- 

### 3. Which of the following best represents a recommendation for laboratory testing for the initial assessment and monitoring of people with HIV?

- A. Only a white blood cell count should be used to monitor people with HIV.
  - B. Only the CD4+ T lymphocyte cell count (or CD4 count) should be used for people with HIV.
  - C. One surrogate marker should be used to monitor people with HIV (e.g., plasma HIV RNA [viral load] to assess level of HIV viremia).
  - D. Two surrogate markers should be used to monitor people with HIV: plasma HIV RNA (viral load) to assess level of HIV viremia and CD4+ T lymphocyte cell count (or CD4 count) to assess immune function.
- 

### 4. Which of the following statements is most accurate?

- A. ART cannot be initiated before drug-resistance test results are available.
  - B. ART cannot be initiated for patients over the age of 65 before drug-resistance test results are available.
  - C. ART cannot be initiated for patients over the age of 75 before drug-resistance test results are available.
  - D. ART can be initiated before drug-resistance test results are available.
- 

### 5. Which of the following best represents a recommendation for antiretroviral therapy to prevent sexual transmission of HIV?

- A. All persons with HIV should be informed that maintaining a plasma HIV RNA (viral load) of <400 copies/mL, including any measurable value below this threshold value, with ART prevents

sexual transmission of HIV to their partners.

B. All persons with HIV should be informed that maintaining a plasma HIV RNA (viral load) of <300 copies/mL, including any measurable value below this threshold value, with ART prevents sexual transmission of HIV to their partners.

C. All persons with HIV should be informed that maintaining a plasma HIV RNA (viral load) of <200 copies/mL, including any measurable value below this threshold value, with ART prevents sexual transmission of HIV to their partners.

D. All persons with HIV should be informed that maintaining a plasma HIV RNA (viral load) of <200 copies/mL, including any measurable value below this threshold value, with ART does not prevent sexual transmission of HIV to their partners.

---

**6. Which of the following best represents a recommendation for the management of the treatment-experienced patient with virologic failure?**

A. Drug-resistance testing should be performed while the patient is taking the failing ARV regimen or within two weeks of treatment discontinuation of a non-long-acting ARV regimen.

B. Drug-resistance testing should be performed while the patient is taking the failing ARV regimen or within four weeks of treatment discontinuation of a non-long-acting ARV regimen.

C. Drug-resistance testing should be performed while the patient is taking the failing ARV regimen or within eight weeks of treatment discontinuation of a non-long-acting ARV regimen.

D. Drug-resistance testing should not be performed.

---

**7. Which of the following best represents a recommendation for treatment-experienced patients with poor CD4 cell recovery and persistent inflammation despite viral suppression?**

A. Interleukin-2 is recommended to increase CD4 cell counts and/or decrease immune activation for all patients.

B. Interleukin-2 is recommended to increase CD4 cell counts and/or decrease immune activation for male patients over the age of 65.

C. Interleukin-2 is recommended to increase CD4 cell counts and/or decrease immune activation for female patients over the age of 65.

D. Interleukin-2 is not recommended to increase CD4 cell counts and/or decrease immune activation, because clinical trial data demonstrated no clinical benefit.

---

**8. A health care administrator has questions regarding cryptococcosis. Which of the following informational points of interest should be communicated to the health care administrator?**

A. Cryptococcosis is caused by a fungus; the fungus typically enters the body through the lungs and can cause pneumonia.

B. Cryptococcosis is caused by a virus; the virus typically enters the body through the lungs and can cause pneumonia.

C. Cryptococcosis is caused by a parasite; the parasite typically enters the body through the lungs and can cause pneumonia.

D. Cryptococcosis cannot cause pneumonia.

---

**9. Which of the following OIs is caused by a virus?**

- A. Histoplasmosis
  - B. Kaposi's sarcoma
  - C. Tuberculosis
  - D. Toxoplasmosis
- 

**10. A health care administrator is developing an educational lecture focused on HIV/AIDS and COVID-19. Which of the following informational points of interest should be included in the health care administrator's lecture?**

- A. COVID-19 treatments cannot interact with ART used to treat HIV.
  - B. Research indicates that currently available medications used to treat or prevent COVID-19 will not interact with PrEP to prevent HIV.
  - C. There is an association between COVID-19 vaccines and risk for HIV infection.
  - D. COVID-19 vaccines are not safe for older adults with HIV.
- 

Copyright © 2025 Care CEUs

Visit us at <https://www.careceus.com>